International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

New App Available to Measure Quality of Life for People with Skin Conditions

Dermatology Quality of Life Index Graphic

Researchers at Cardiff University have created and launched The Official DLQI App, designed to measure the quality of life for people with skin conditions. The app is free to download in the Apple and Android stores and is now available in seven languages: English (United Kingdom and United States), Spanish, German, French, Japanese, Hindi, and Simplified Chinese. If the user’s phone is set to one of these languages, the app will automatically download in that language. Otherwise, the app will download in English.

This straightforward app gives an instant DLQI score and gives the score’s meaning. The five most recent results are stored and displayed. The individual smartphone keeps the data confidential and is not available to anyone else.

Download the App Now!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



Recent Posts

Expert Insights IPC and IFPA CEO

IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives

New Councilor Headshots

Meet Our Newest Councilors

IPC and IFPA strongly advocate that early diagnosis is crucial and must be available for all individuals regardless of race, ethnicity, physical ability, culture, nationality, or geographic location blog graphic

IPC and IFPA Joint Statement on Diversity and Inclusion

Also Read

Commentary -Peter van de Kerkhof headshot
Peter van de Kerkhof

Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial

Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.